|
1）Berzigotti A, Seijo S, Arena U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology. 2013; 144: 102-11 e1
|
|
|
|
|
2）Sharma P, Kirnake V, Tyagi P, et al. Spleen stiffness in patients with cirrhosis in predicting esophageal varices. Am J Gastroenterol. 2013; 108: 1101-7
|
|
|
|
|
3）Sporea I, Ratiu I, Sirli R, et al. Value of transient elastography for the prediction of variceal bleeding. World J Gastroenterol. 2011; 17: 2206-10
|
|
|
|
|
|
4）Takuma Y, Nouso K, Morimoto Y, et al. Measurement of spleen stiffness by acoustic radiation force impulse imaging identifies cirrhotic patients with esophageal varices. Gastroenterology. 2013; 144: 92-101 e2
|
|
|
|
|
|
5）Bota S, Sporea I, Sirli R, et al. Can ARFI elastography predict the presence of significant esophageal varices in newly diagnosed cirrhotic patients? Ann Hepatol. 2012; 11: 519-25
|
|
|
|
|
|
6）Bajaj JS, Ahluwalia V, Wade JB, et al. Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis. J Hepatol. 2013; 58: 38-44
|
|
|
|
|
|
7）Ahluwalia V, Wade JB, Thacker L, et al. Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. J Hepatol. 2013; 59: 467-73
|
|
|
|
|
|
8）Eslam M, Ampuero J, Jover M, et al. Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables. Ann Hepatol. 2013; 12: 588-98
|
|
|
|
|
|
9）Zoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2013; 62: 760-5
|
|
|
|
|
|
10）Wong GL, Chan HL, Mak CH, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013. In press
|
|
|
|
|
|
11）Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther. 2012; 35: 674-89
|
|
|
|
|
|
12）Bourliere M, Wendt A, Fontaine H, et al. How to optimize HCV therapy in genotype 1 patients with cirrhosis. Liver Int. 2013; 33 Suppl 1: 46-55
|
|
|
|
|
|
13）Lok AS, Everhart JE, Wright EC, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011; 140: 840-9; quiz e12
|
|
|
|
|
|
14）Bajaj JS, Ridlon JM, Hylemon PB, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2012; 302: G168-75
|
|
|
|
|
|
15）Bajaj JS, Hylemon PB, Ridlon JM, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012; 303: G675-85
|
|
|
|
|
|
16）Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013; 8: e60042
|
|
|
|
|
|
17）Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013; 28: 450-5
|
|
|
|
|
|
18）Shukla S, Shukla A, Mehboob S, et al. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther. 2011; 33: 662-71
|
|
|
|
|
|
19）Sharma P, Agrawal A, Sharma BC, et al. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol. 2011; 26: 996-1003
|
|
|
|
|
|
20）Agrawal A, Sharma BC, Sharma P, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012; 107: 1043-50
|
|
|
|
|
|
21）Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013; 108: 1458-63
|
|
|
|
|
|
22）Zullo A, Hassan C, Ridola L, et al. Rifaximin therapy and hepatic encephalopathy: Pros and cons. World J Gastrointest Pharmacol Ther. 2012; 3: 62-7
|
|
|
|
|
|
23）Bajaj JS, Pinkerton SD, Sanyal AJ, et al. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology. 2012; 55: 1164-71
|
|
|
|
|
|
24）Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International society for hepatic encephalopathy and nitrogen metabolism consensus. Hepatology. 2013; 58: 325-36
|
|
|
|
|
|
25）Kato A, Tanaka H, Kawaguchi T, et al. Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: A preliminary, prospective, open-label study. Hepatol Res. 2013; 43: 452-8
|
|
|
|
|
26）Malaguarnera M. Acetyl-L-carnitine in hepatic encephalopathy. Metab Brain Dis. 2013; 28: 193-9
|
|
|
|
|
|
27）Sakaida I, Kawazoe S, Kajimura K, et al. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2013. In press
|
|
|
|
|
|
28）Sakaida I, Yamashita S, Kobayashi T, et al. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. J Int Med Res. 2013; 41: 835-47
|
|
|
|
|
|
29）Gaglio P, Marfo K, Chiodo J, 3rd. Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V(2)-receptor antagonist tolvaptan. Dig Dis Sci. 2012; 57: 2774-85
|
|
|
|
|
|
30）Dahl E, Gluud LL, Kimer N, et al. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Aliment Pharmacol Ther. 2012; 36: 619-26
|
|
|
|
|
|
31）Kalambokis GN, Mouzaki A, Rodi M, et al. Rifaximin for the prevention of spontaneous bacterial peritonitis. World J Gastroenterol. 2012; 18: 1700-2
|
|
|
|
|
|
32）Hanouneh MA, Hanouneh IA, Hashash JG, et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol. 2012; 46: 709-15
|
|
|
|
|
|
33）Goel GA, Deshpande A, Lopez R, et al. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol. 2012; 10: 422-7
|
|
|
|
|
|
34）Siple JF, Morey JM, Gutman TE, et al. Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites. Ann Pharmacother. 2012; 46: 1413-8
|
|
|
|
|